![]() ![]() Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Backtested performance is developed with the benefit of hindsight and has inherent limitations. This information is provided for illustrative purposes only. No representations and warranties are made as to the reasonableness of the assumptions. Certain assumptions have been made for modeling purposes and are unlikely to be realized. Changes in these assumptions may have a material impact on the backtested returns presented. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested performance is not an indicator of future actual results. ![]() Shares have declined 10% year-to-date.ĭisclaimer: The TipRanks Smart Score performance is based on backtested results. ![]() The average AMGN stock price target of $259 implies a possible upside of 10.9% from current levels. Wall Street is currently sidelined on Amgen stock, with a Hold consensus rating based on five Buys, five Holds, and two Sells. At the same time, Senator Elizabeth Warren sent a letter to the FTC stating her concerns about the merger. In January, the FTC sent a second request to both parties, asking them to provide further information and documentation about the transaction. It is worth mentioning that the deal was criticized from the start. Through this buyout, Amgen aimed to boost its innovative therapeutics portfolio by adding Horizon’s expertise in rare disease drug development. The acquisition, announced in December 2022, was expected to close in the first half of this year. The regulator is expected to file a lawsuit later today stating that the deal might impact competition in drug development, Bloomberg reported. Federal Trade Commission (FTC) is preparing to block Amgen’s ( NASDAQ:AMGN) $27.8 billion deal to buy Horizon. The decline might be attributed to rumors that the U.S. Shares of Horizon Therapeutics ( NASDAQ:HZNP) fell 16% in yesterday’s after-trade and another 18% at the time of writing. ![]()
0 Comments
Leave a Reply. |